Oxurion launches Exagis' eTMF module to optimize clinical trials

Oxurion NV, a biopharmaceutical company based in Leuven, has announced the commercial launch of its eTMF module, a key component of its Exagis platform. This development reinforces their strategy of creating a modular and comprehensive eClinical solution.

The eTMF (electronic Trial Master File) module aims to centralize essential clinical trial documentation. It is designed to improve regulatory compliance and facilitate collaboration among stakeholders. It contributes to improved operational efficiency and oversight of clinical trials.

Exagis was developed by Axiodis CRO, a subsidiary of Oxurion, leveraging proven clinical expertise. The eTMF module represents a significant milestone for the platform, and further features integrating artificial intelligence and operational analytics are planned for the future.